An interventional study of Counselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study) and Dairy (short-term study) in Dairy Consumption, Metabolic Health and Obesity Prevention, sponsored by University of Toronto. Recruiting at 2 sites in Canada. Open to participants aged 14 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-05.
Sponsored by University of Toronto · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Obesity by University of Toronto — 4 open to participants now, 7 under way, none of them phase 3. Obesity · University of Toronto.
Among the 53 studies in Obesity by University of Toronto, this one has the largest planned enrollment of the 38 interventional ones that give a count, is the only one that started in 2026, is one of 36 with no phase, and was the 53rd registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →4 of the 53 studies in Obesity by University of Toronto are open now, in 1 country. Recruiting first, the newest first:
University of Toronto · Sites in Canada
Ages 40+
University of Toronto · Sites in Canada
Women only · Healthy volunteers
University of Toronto · Sites in Canada
Ages 18–45 · Healthy volunteers
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 14 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3
First in 2002; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 240 is above the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 30 across the 38 interventional studies, 1 across the 12 observational. Of the 35 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Toronto is the lead sponsor of 405 studies on the registry; 51 are open to participants now.
3 of the studies in Obesity by University of Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06781762University of TorontoShort-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer | 2026-12-30 |
| NCT06879652University of TorontoThe Effect of Dairy Intake on Body Weight and Composition and Metabolic Health in Adolescents and Seniors | 2027-06 |
| NCT06118931University of TorontoTime-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control | 2027-06-28 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Obesity by University of Toronto, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to examine how regular dairy intake affects body weight, body composition, and metabolic health in overweight and obese adolescents (ages 15-18) and older adults (ages 60-80) over six months. We are inviting eligible individuals to participate in this study at the Nutrition Intervention Center, Department of Nutritional Sciences, University of Toronto. Participants will be randomly divided into two groups. The intervention (dairy) group will consume three servings of dairy per day (milk, yogurt, and cheese) before breakfast, lunch, and dinner. The control (low-dairy) group will continue their usual diet, keeping dairy intake to less than one serving per day.
Participants will have biweekly sessions with a registered dietitian to be guided to follow Canada's Food Guide, monitor their dietary intake and ensure compliance with their assigned group. In addition, they will visit the Nutrition Intervention Center at weeks 0, 12, and 24 for anthropometric and body composition assessments (weight, height, waist circumference, blood pressure, lean mass, and fat mass), resting metabolic rate, (gait speed, grip strength, and chair stand test just for older adults) and blood markers (fasting blood glucose, insulin, C-peptide, HbA1c, lipid profiles, and inflammatory markers). Each visit will take approximately 4 hours.
Before each visit, the participants will be asked to fast overnight for 12 hours, maintain their usual diet and sleep patterns, and avoid exercise and alcohol the day before. The participants will be compensated for their time and travel expenses.
Our secondary objective is to compare the effects of dairy and plant-based alternative products on blood sugar and appetite regulation in adolescents and older adults. Participants will be asked to come to the Nutrition Intervention Center on 3 separate occasions: once for an in-person screening lasting approximately 30 min and 2 times for study visits lasting approximately 2.5 hrs each. The entire study will take at least 2 weeks to complete. You will be asked to fast for 12 hrs (overnight) before each study visit. You will also be instructed to maintain the same dietary and sleep patterns and refrain from exercise and alcohol consumption on the days before the study visits. During these study visits, you will be asked to consume either a dairy or a plant-based alternative product as well as a pizza meal. You will periodically fill out questionnaires rating your feelings and perceptions, and provide blood samples through finger pricks and intravenously through your forearm to measure blood sugar, insulin, hormones, and amino acids. You will be compensated for your time and travel expenses.
Inclusion Criteria (long-term Study):
Exclusion Criteria:
Inclusion Criteria (short-term study):
Exclusion Criteria (short-term study):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the intervention group will follow Canada's Food Guide and consume 3 servings of dairy per day.
Other: Counselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study)
Participants in the control group will adhere to Canada's Food Guide and keep their dairy intake to less than one serving per day.
Other: Counselling to follow Canada's Food Guide (long-term study)
Participants in the intervention group will follow Canada's Food Guide and consume 3 servings of dairy per day.
Other: Counselling to follow Canada's Food Guide and 3 daily servings of Dairy (long-term study)
Participants in the control group will adhere to Canada's Food Guide and keep their dairy intake to less than one serving per day.
Other: Counselling to follow Canada's Food Guide (long-term study)
Participants will consume 2 servings of dairy milk or yogurt.
Other: Dairy (short-term study)
Participants will consume 2 servings of a commercially available soy milk or plant-based yogurt.
Other: Plant-based alternative (short-term study)
Participants will consume 2 servings of dairy milk or yogurt.
Other: Dairy (short-term study)
Participants will consume 2 servings of a commercially available soy milk or plant-based yogurt.
Other: Plant-based alternative (short-term study)
Participants aged 15-18 and 60-80 years who are randomly assigned to the intervention group will follow Canada's Food Guide and consume 3 servings of dairy (milk, yogurt, cheese) per day for 24 weeks.
The dairy products that participants will be required to consume include: 1) Trial 1: 2% cow's milk; 2) Trial 2: dairy yogurt.
Participants will be instructed to follow Canada's Food Guide.
The plant-based products that participants will be required to consume include: 1) Trial 1: soy beverage; 2) Trial 2: plant-based yogurt;
Body Fat Mass (kg)
Body Fat Mass (BFM) is the primary outcome in the long-term study of the senior group. It will be measured using bioelectrical impedance analysis (BIA).
Time frame: BFM will be measured at weeks 0, 6, 12, 18, and the end of the study (week 24).
Lean body mass (Kg)
Lean body mass (LBM) is the primary outcome in the long-term study of the senior group. It will be measured using bioelectrical impedance analysis (BIA).
Time frame: LBM will be measured at weeks 0, 6, 12, 18, and the end of the study (week 24).
Body Mass Index (BMI) z-score
BMI z-score, the primary outcome in the long-term study of the adolescent group, is an age- and sex-adjusted measure of BMI in adolescents. It will be calculated using height and weight measurements and interpreted using WHO growth charts and percentiles.
Time frame: BMI z-score will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Blood Glucose (mmol/L) (short-term study)
Blood glucose, the primary outcome in the short-term studies of adolescents and seniors, will be measured via finger-prick using a glucometer at 0, 5, 20, 35, 50, 65, 95, 125, and 145 minutes after treatment consumption.
Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.
Fasting blood glucose (FBG) (mmol/L)
FBS will be measured to assess glycemic control in long-term studies of adolescents and seniors. It will be measured using a finger-prick blood sample and a glucometer after a 12-hour overnight fast.
Time frame: FBS will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
HbA1c (%)
HbA1c measures average blood glucose levels over the past 2-3 months. It will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: HbA1c will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Insulin (µU/mL)
Insulin levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: Insulin will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
C-Peptide (pmol/L)
C-peptide levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: C-Peptide will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
HOMA-IR will be calculated as (Fasting Insulin \[µU/mL\] × Fasting Glucose \[mmol/L\]) / 22.5 to assess insulin resistance in long-term studies of adolescents and seniors.
Time frame: HOMA-IR will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Total cholesterol (TC) (mmol/L)
TC levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: TC will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Low-density lipoprotein cholesterol (LDL-C) (mmol/L)
LDL-C levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: LDL-C will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
High-density lipoprotein cholesterol (HDL-C) (mmol/L)
HDL-C levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: HDL-C will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Triglycerides (mmol/L)
Triglyceride levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: Triglycerides will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
C-Reactive protein (CRP) (mg/L)
CRP, a marker for assessing systemic inflammation, will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: CRP will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Interleukin-6 (IL-6) (pg/mL)
Interleukin-6 levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: Interleukin-6 will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Leptin (ng/mL)
Leptin levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: Leptin will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Adiponectin (µg/mL)
Adiponectin levels will be measured in plasma obtained through intravenous blood collection after a 12-hour overnight fast in long-term studies of adolescents and seniors.
Time frame: Adiponectin will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Resting Metabolic Rate (RMR) (kcal/day)
RMR will be measured using indirect calorimetry after an overnight fast and at least 30 minutes of rest in a thermoneutral environment.
Time frame: RMR will be measured at the beginning (week 0) and end of the study (week 24).
Blood pressure (BP) (mmHg)
Blood pressure will be measured in long-term studies of adolescents and seniors, using an automated sphygmomanometer after the participant has been seated and at rest for 10 minutes.
Time frame: BP will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Waist circumference (WC) (cm)
WC will be measured in long-term studies of adolescents and seniors to assess abdominal adiposity using a standardized measuring tape at the midpoint between the lowest rib and the iliac crest while the participant is in a standing position.
Time frame: WC will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Body Mass Index (BMI) (kg/m²)
BMI will be calculated to assess overall adiposity in seniors using weight and height measurements, applying the formula: BMI = weight (kg) / height (m²).
Time frame: BMI will be measured at the beginning (week 0), midpoint (week 12), and end of the study (week 24).
Gait speed (m/s)
Gait speed will be assessed in a long-term study of seniors using a standardized 4-meter walk test as an indicator of physical function.
Time frame: Gait speed will be measured at weeks 0, 6, 12, 18, and 24.
Grip strength (kg)
Grip strength will be assessed in the long-term study of seniors, using a hand dynamometer as a measure of muscle strength.
Time frame: Grip strength will be measured at weeks 0, 6, 12, 18, and 24.
Chair stand test
The 30-second chair stand test will be used to assess lower-body strength in the long-term study of seniors. The number of completed stands within 30 seconds will be recorded.
Time frame: The chair stand test will be performed at weeks 0, 6, 12, 18, and 24.
Urinary Urea Nitrogen (UUN)
Urinary urea nitrogen will be measured from a complete 24-hour urine collection in a subset of participants to estimate dietary protein intake and nitrogen balance in this long-term study of seniors.
Time frame: Urinary urea nitrogen will be measured at baseline (week 0) and at week 24.
Insulin (µU/mL) (short-term study)
Insulin will be measured in the plasma through intravenous blood collection at 0, 35, 65, 125, and 145 minutes after treatment consumption.
Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.
C-peptide (nmol/L) (short-term study)
C-peptide will be measured in the plasma through intravenous blood collection at 0, 35, 65, 125, and 145 minutes after treatment consumption.
Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.
Glucagon-like Peptide-1 (GLP-1) (short-term study)
GLP-1 will be measured in the plasma through intravenous blood collection at 0, 35, 65, 125, and 145 minutes after treatment consumption.
Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.
Amino acids (µmol/L) (short-term study)
Amino acid concentrations will be measured in the plasma through intravenous blood collection at 0, 35, 65, 125, and 145 minutes after treatment consumption.
Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.
Subjective Appetite (short-term study)
Subjective appetite will be assessed through Adaptive Visual Analogue Scales (AVAS) questionnaires completed at 0, 5, 20, 35, 50, 65, 95, 125 and 145 minutes after treatment consumption and through an ad libitum pizza meal provided at 125 minutes post-treatment consumption, where participants will be instructed to eat until they are comfortably full over 20 minutes.
Time frame: Over 145 minutes after treatment consumption at each session, for a total of 2 weekly sessions.
Food intake (Kcal) (short-term study)
Ad libitum food intake (kcal) will be assessed during a standardized pizza meal provided 2 hours after treatment consumption, consumed over 20 minutes.
Time frame: Assessed from 125 to 145 minutes following treatment consumption.
Dietary intake
Dietary intake and adherence to Canada's Food Guide will be assessed using a 3-day food record, the modified Canadian Food Intake Screener (mCFIS), the Canadian Eating Practices Screener (CEPS), and a knowledge, attitude, and practice questionnaire (KAPQ).
Time frame: Three-day food records will be collected every six weeks; the mCFIS and CEPS will be administered monthly; and the KAPQ will be administered at weeks 0, 12, and 24.
Plan to share: No — IPD will not be shared, as all data will be de-identified and pooled during the analysis. Only researchers directly involved in the study will have access to the data.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.